Longjin Pharmaceutical(002750)

Search documents
今年来第四家!昔日明星药企,今成A股黄花!
IPO日报· 2025-05-29 14:38
Core Viewpoint - *ST Longjin (002750.SZ) has been announced for delisting by the Shenzhen Stock Exchange due to continuous financial losses and failure to meet revenue thresholds [1][7]. Company Overview - *ST Longjin, officially known as Kunming Longjin Pharmaceutical Co., Ltd., was established in September 1996 and listed on the Shenzhen Stock Exchange in 2015. The company focuses on the development, research, production, and sales of therapeutic drugs for cardiovascular and metabolic diseases, with its main product being the Longjin injection of Ligusticum chuanxiong [5]. - The company experienced stable revenue growth in its first three years post-listing, with revenues of 181 million, 224 million, and 304 million yuan, and net profits of 54 million, 58 million, and 19 million yuan respectively from 2015 to 2017. However, since 2018, the company's profitability has sharply declined, with net profits remaining negative from 2019 onwards [5][7]. Financial Performance - In 2024, *ST Longjin reported annual revenue of 66 million yuan, a year-on-year decline of 23.25%, marking five consecutive years of revenue below 100 million yuan. The net loss was 41 million yuan, although this represented a 41.58% improvement year-on-year. However, the company still reported a non-recurring net loss of 50 million yuan [7]. - The company's reliance on a single product, the Longjin injection, has been detrimental, as this product has consistently accounted for over 90% of its revenue. Following regulatory changes and price reductions, the sales volume of this product dropped significantly, leading to a devastating impact on the company's financial health [8][9]. Market Challenges - The Longjin injection's sales fell by nearly 20% in 2017 due to regulatory warnings about severe allergic reactions. In 2021, the product's price was drastically reduced by 67% during a procurement process, leading to a further decline in sales [8]. - The company has attempted to diversify its product offerings and explore new markets, including industrial hemp, but these efforts have largely failed. The industrial hemp initiative faced regulatory challenges and a reduction in planting area, while the development of cardiovascular generic drugs has been slow, with the first product only receiving approval at the end of 2024 [10][11]. Industry Context - Since 2025, three other traditional Chinese medicine injection companies have also faced delisting from the A-share market due to similar financial struggles, highlighting a broader trend of challenges within the industry [12].
靠灯盏花素闻名的龙津药业退市在即
Xin Lang Cai Jing· 2025-05-29 10:59
Core Viewpoint - Longjin Pharmaceutical has received a delisting notice from the Shenzhen Stock Exchange due to continuous financial losses and insufficient revenue, marking a significant decline in its operational performance over the years [1][2]. Company Overview - Longjin Pharmaceutical was established in 1991, initially focusing on the development of injectable drugs, particularly the injection of Ligusticum wallichii, which became its flagship product [3]. - The company has a long history of clinical use for Ligusticum wallichii, with over 11,000 related research papers published [3]. Financial Performance - The company reported a negative net profit for the fiscal year 2023, with operating revenue falling below 1 billion yuan, leading to a delisting risk warning [2]. - Longjin Pharmaceutical's annual revenue has fluctuated between 100 million to 300 million yuan, with a peak of 700 million yuan in 2021, but adjusted revenue was only around 200 million yuan [7]. - The net profit has shown a downward trend, with the adjusted net profit turning negative for the first time in 2019 and remaining negative for six consecutive years until 2024 [7][8]. Business Challenges - The company attributes its poor performance to policy impacts on its main product, including restrictions on medical insurance coverage and centralized procurement policies [9]. - Longjin Pharmaceutical has struggled to diversify its product line beyond its flagship product, despite efforts in research and external investments [9]. - The company has attempted to pivot towards pharmaceutical promotion services and personal care products, but these ventures have not yet turned profitable and face high operational costs [9].
5月29日早间重要公告一览
Xi Niu Cai Jing· 2025-05-29 04:04
Group 1 - Sun Cable's shareholder plans to reduce its stake by up to 3% of the company's shares, amounting to 21.67 million shares, due to operational needs [1] - China Chemical's controlling shareholder has secured a loan commitment of up to 540 million yuan to support its share buyback plan, which aims to purchase between 300 million and 600 million yuan worth of shares within 12 months [1] Group 2 - Palm Holdings has initiated legal proceedings over a loan dispute involving over 149 million yuan, which represents 8.99% of the company's latest audited net assets [2] - Zhongtai Securities' application for a specific stock issuance has been accepted by the Shanghai Stock Exchange, pending further regulatory approval [4] Group 3 - Tongda Electric's stock has seen a significant increase of 30.01% over three consecutive trading days, raising concerns about potential market overheating and irrational speculation [5] - Huaneng International plans to apply for public REITs based on its Qingdao project, involving a transfer of project company shares and strategic participation from related parties [7] Group 4 - Longjian Shares' application for issuing convertible bonds has been approved by the Shanghai Stock Exchange, pending further registration approval from the China Securities Regulatory Commission [7] - Hehe Information is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global capital operations [8] Group 5 - ST Huaxi has signed a significant overseas contract worth approximately 2.9 billion yuan for the reconstruction of a power plant in Iraq, although the contract's effectiveness is subject to certain conditions [9] - Zhongqi Shares has project approval for a chemical product but has not yet commenced production, indicating limited impact from recent industry incidents [11] Group 6 - Sino Medical's subsidiary has received a medical device registration certificate for a new stent product, marking a significant advancement in its product offerings [14] - *ST Longjin's stock is entering a delisting preparation period, with trading expected to last for 15 days [15] Group 7 - Chao Da Equipment has undergone a change in controlling shareholder, with a significant portion of shares transferred to Nanjing Youxu [15] - *ST Wan Fang plans to transfer a 68.88% stake in a subsidiary for 7.6 million yuan, ceasing its financial consolidation with the subsidiary [16] Group 8 - Zhejiang Construction's subsidiary has won a framework contract for a residential redevelopment project valued at approximately 1.2 billion yuan, expected to positively impact the company's performance [17] - China Gold's controlling shareholder plans to increase its stake in the company by investing between 168 million and 335 million yuan [18] Group 9 - Tianhong Shares' major shareholder intends to reduce its stake by up to 3%, amounting to 35.07 million shares, due to personal funding needs [18] - Lingdian Electric Control is planning to acquire a 98.43% stake in a company for 478 million yuan to consolidate resources in the automotive electronics sector [19] Group 10 - Tianyuan Pet is planning to acquire an 89.71% stake in a technology company, with funding to be raised through a share issuance [19] - Beijing Culture's major shareholder plans to reduce its stake by up to 3%, amounting to 21.48 million shares, due to operational funding needs [20]
盘前必读丨MSCI纳A指数样本调整将生效;美联储公布5月议息会议纪要
Di Yi Cai Jing· 2025-05-28 23:51
Group 1 - The overall market liquidity remains tight, with structural market conditions leading to rotations in new consumption and new manufacturing sectors [1][18] - There are left-side investment opportunities in fields such as robotics, intelligent driving, and internet platforms [1][18] - The basic chemical industry is currently undervalued, presenting medium to long-term investment potential [18] Group 2 - The performance of sectors like consumption and pharmaceuticals is expected to be relatively stable, with short-term elasticity likely to be better [18] - The chemical industry is anticipated to see structural opportunities and valuation recovery in 2025, driven by policy stimulus and improving demand [18] - The supply side of the chemical industry is experiencing a slowdown in capital expenditure and new capacity growth, which will take time to digest [18]
晚间公告丨5月28日这些公告有看头
第一财经· 2025-05-28 15:17
Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have announced significant developments, including regulatory actions, acquisitions, capital increases, and stock listings, which may present investment opportunities and risks for investors [2]. Regulatory Actions - Jiaying Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [3]. - *ST Longjin has received a decision from the Shenzhen Stock Exchange to terminate its stock listing, effective June 27, 2025, due to its stock price being below 1 yuan for twenty consecutive trading days [11][12]. Mergers and Acquisitions - ST United plans to acquire 100% of Runtian Industrial through a combination of share issuance and cash payment, aiming to enhance its positioning in the cultural tourism consumption sector [4]. - Longgao Co. is undergoing a restructuring of its controlling shareholder, Longyan Investment Development Group, which will become a wholly-owned subsidiary of the newly established investment development group with a registered capital of 3 billion yuan [6]. Capital Increases - Sanyou Chemical's controlling shareholder plans to increase capital by 100 million yuan in its subsidiary, Sanyou Silicon Industry, through a private agreement, with no changes to the consolidation scope [7]. Stock Listings - Shantui Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries [9]. - Hehe Information intends to issue H-shares and apply for a listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [10]. Share Buybacks and Increases - China Gold's controlling shareholder plans to increase its stake in the company by 168 million to 335 million yuan within 12 months [13]. - Taiji Industry intends to repurchase shares worth 100 million to 120 million yuan, with the repurchased shares to be canceled [14]. Major Contracts - China Energy Construction's subsidiary has won a coal power project contract worth approximately 14.586 billion yuan [15]. - ST Huaxi has signed a significant contract worth about 2.9 billion USD (approximately 20.84 billion yuan) for the restoration of a power plant in Iraq, which represents 80.38% of its latest audited revenue [16].
5月28日重要资讯一览
Zheng Quan Shi Bao Wang· 2025-05-28 14:09
Group 1: Economic and Industry Updates - China announced a unilateral visa exemption policy for Saudi Arabia, Oman, Kuwait, and Bahrain, effective from June 9, 2025, to June 8, 2026, allowing ordinary passport holders to enter China for up to 30 days without a visa [1] - The Ministry of Finance reported that from January to April 2025, the total operating revenue of state-owned and state-controlled enterprises was 262,755.0 billion yuan, remaining flat year-on-year, while total profit decreased by 1.7% to 13,491.4 billion yuan [2] - A meeting on semiconductor cooperation between China and the EU emphasized the importance of collaboration in the global semiconductor supply chain, with a commitment to oppose unilateralism and ensure supply chain stability [2] - The National Healthcare Security Administration announced a verification of retail pharmacy pharmacists to ensure compliance with labor contracts and prohibit "hanging certificates" or part-time practices [2] Group 2: Company News - Zhongqi Co. has project approval for chlorantraniliprole but has not yet commenced production [4] - Tongda Electric's stock may be subject to market sentiment risks and irrational speculation [4] - ST Longjin's stock will enter the delisting arrangement period starting June 6 [4] - Yaxing Chemical's subsidiary plans to introduce strategic investors [4] - China Gold's controlling shareholder intends to increase its stake in the company by 168 million to 335 million yuan [4] - ST Huaxi signed a significant contract worth 290 million USD for daily operations [4] - Shantui Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [5] - Hehe Information is also planning to issue H-shares for listing on the Hong Kong Stock Exchange [5] - Debon Logistics stated that the current trends in autonomous logistics vehicles will not impact its performance [5] - ST Jiyuan's stock will be delisted on May 29 [5] - ST United plans to acquire 100% of Runtian Industrial and will resume trading on May 29 [5] - Taiji Industry intends to repurchase shares worth 100 million to 120 million yuan [5] - China Energy Construction's subsidiary won a coal and power project contract worth approximately 145.86 billion yuan [5]
*ST龙津(002750) - 关于公司股票进入退市整理期交易的公告
2025-05-28 11:18
股票代码:002750 股票简称:*ST 龙津 公告编号:2025-051 昆明龙津药业股份有限公司 关于公司股票进入退市整理期交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 特别提示: 1、公司股票进入退市整理期的起始日为 2025 年 6 月 6 日,退市整理期为十 五个交易日,预计最后交易日期为 2025 年 6 月 26 日。公司股票于退市整理期届 满的次一交易日摘牌,公司股票终止上市。 2、退市整理期交易期间,公司将不筹划或实施重大资产重组事项。 3、请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 4、对于将在股票摘牌后至完成全国中小企业股份转让系统有限责任公司依 托原证券公司代办股份转让系统设立并代为管理的两网公司及退市公司板块(以 下简称"退市板块")初始登记期间到期的司法冻结业务,建议有权机关在股票 摘牌前通过原协助执行渠道提前办理续冻手续。 昆明龙津药业股份有限公司(以下简称"公司")于 2025 年 5 月 28 日收到 深圳证券交易所(以下简称"深交所")送达的《关 ...
*ST龙津(002750) - 关于收到股票终止上市决定的公告
2025-05-28 11:18
股票代码:002750 股票简称:*ST 龙津 公告编号:2025-050 昆明龙津药业股份有限公司 关于收到股票终止上市决定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 特别提示: 1、终止上市的证券种类:人民币普通股,证券简称:*ST 龙津,证券代码: 002750,终止上市日期:2025 年 6 月 27 日。 2、公司股票于 2025 年 6 月 6 日复牌并进入退市整理期,退市整理期的交易 期限为十五个交易日,预计最后交易日期为 2025 年 6 月 26 日。 3、退市整理期间股票在风险警示板交易。退市整理期首个交易日,公司股 票价格无涨跌幅限制,此后每日涨跌幅限制为 10%。 4、请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 5、对于将在股票摘牌后至完成全国中小企业股份转让系统有限责任公司依 托原证券公司代办股份转让系统设立并代为管理的两网公司及退市公司板块(以 下简称"退市板块")初始登记期间到期的司法冻结业务,建议有权机关在股票 摘牌前通过原协助执行渠道提前办理续冻手续 ...
*ST龙津(002750) - 2024年年度股东会法律意见书
2025-05-21 12:30
建纬(昆明)律师事务所 关于昆明龙津药业股份有限公司 2024年年度股东会 法律意见书 二〇二五年五月二十一日 建纬(昆明)律师事务所 关于昆明龙津药业股份有限公司 2024 年 度 股东会的法律意见书 为出具本法律意见书,本所律师对公司本次股东会所涉及的有 关事项进行了审查,查阅了公司提供的本次股东会有关文件和资料, 同时听取了公司人员就有关事实的陈述和说明。 公司已向本所承诺:公司所提供的文件和所作陈述及说明是完 整、真实和有效的,有关原件及其上面的签字和印章是真实的,且 一切足以影响本法律意见书的事实和文件均已向本所披露,无任何 隐瞒、疏漏之处。 本所律师仅根据本法律意见书 出具日以前发生或存在的事实及 有关的法律、行政法规、规范性文件发表法律意见。本所律师仅对 本次股东会的召集和召开程序,参加会议的人员资格,会议召集人 资格,及会议表决程序、表决结果是否符合有关法律、行政法规、规 范性文件及《公司章程》的规定发表意见,并不对会议所审议的提 案内容及该等提案所表述的事实或数据的真实性和准确性发表意见。 本法律意见书仅供公司为本次股东会之目的使用,不得用于其 他任何目的或用途。本所同意,公司可以将本法律意 ...
*ST龙津(002750) - 2024年年度股东会决议公告
2025-05-21 12:30
股票代码:002750 股票简称:*ST 龙津 公告编号:2025-049 昆明龙津药业股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东会未出现否决提案的情形。 2、本次股东会未涉及变更以往股东会决议的情形。 一、会议召开和出席情况 (一)会议召开情况 1、通知公告时间:2025 年 4 月 24 日(公告编号:2025-038) 2、会议召开时间:2025 年 5 月 21 日 14:00 3、会议召开地点:云南省昆明高新区马金铺街道办事处兰茂路 789 号公司 办公大楼五楼会议室 4、会议召开方式:现场投票与网络投票相结合的方式 5、会议召集人:本公司董事会 6、会议主持人:董事长樊献俄先生 7、股权登记日:2025 年 5 月 15 日 本次会议的召集、召开符合《公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的有关规定。 总表决情况: 同意 200,400,874 股,占出席本次股东会有效表决权股份总数的 99.4239%; 反对935,800股,占出席本次股东会有 ...